US 10233244
Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
granted A61KA61K2039/505A61K47/68031
Quick answer
US patent 10233244 (Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 48
- CPC classes
- A61K, A61K2039/505, A61K47/68031, A61K47/68033, A61K47/6809